Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 million equity investment by Gilead in Arcus common stock at $21.00 per share. This strategic investment and collaboration amendment are set to accelerate the growth of their joint development programs […]
Biopharmaceutical firm Gilead Sciences (Nasdaq: GILD) has announced the termination of its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to a lack of promising results, according to a planned analysis. The safety data observed during the trial was found to align with the known profile of magrolimab, an investigational anti-CD47 immunotherapy drug […]
Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According to the US pharma company, the conditional marketing authorization for Veklury was given in the interest of public health because of the coronavirus pandemic […]
Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the treatment of hospitalized patients with moderate pneumonia associated with novel coronavirus, has yielded promising results. According to the US biopharma company, the Covid-19 drug candidate delivered significantly greater clinical improvement for […]
Epclusa FDA approval : Gilead Sciences has secured an expanded approval for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) from the US Food and Drug Administration (FDA), which covers treatment of chronic hepatitis C infection (HCV) in children. The approval is for the drug to be used for the treatment of children aged six […]